Abbott Laboratories (ABT: Quote) said that it will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C or HCV at the International Liver Congress 2012 or ILC 2012, the annual meeting of the European Association for the Study of the Liver or EASL, April 18-22 in Barcelona, Spain.
In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment or SVR12 in 95 percent and 93 percent of treatment-naive genotype 1 or GT1 patients.
In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r. In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment, the company said.
In a separate study, known as "Pilot," 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks or SVR24, Abbott noted.
Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com